ArticleJournal of inflammation research2025
Serum Levels of TNFAIP3 and NLRP3 as Novel Biomarkers for Major Adverse Cardiovascular Events in Patients with Chronic Heart Failure: A Cohort Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Stochastic Sensors Based on Phthalocyanine Complexes for the Detection of C-NP, IL-6, and CRP in Cardiovascular Diseases.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chronic heart failure (CHF) is a major public health issue with high morbidity and mortality, where inflammation plays a key role in its progression. Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) and NOD-like receptor protein 3 (NLRP3) regulate inflammatory responses, but their prognostic value in CHF remains unclear. This study aims to investigate the association between serum levels of TNFAIP3 and NLRP3 and the risk of major adverse cardiovascular events (MACEs) in patients with CHF. Patients and Methods: A cohort study was conducted involving 318 patients with CHF and 122 controls. Serum levels of TNFAIP3 and NLRP3 were measured using enzyme-linked immunosorbent assay method. Propensity score matching (PSM) was used to control for confounders. Multivariable logistic regression, restricted cubic spline, threshold effect, and receiver operating characteristic (ROC) analyses were employed to evaluate the associations between biomarker levels and MACEs over a 6-month follow-up. Results: After PSM, patients with CHF had significantly higher TNFAIP3 and NLRP3 levels than controls (both p < 0.001). Compared to CHF patients without MACEs, those with MACEs exhibited significantly lower levels of TNFAIP3 and higher levels of NLRP3. Multivariable analysis confirmed TNFAIP3 as an independent protective factor [odds ratio (OR)= 0.61, 95% confidence interval (CI): 0.40-0.93) and NLRP3 as an independent risk factor (OR = 1.24, 95% CI: 1.17-1.31) for MACEs. ROC analysis demonstrated NLRP3 (AUROC = 0.756) had better predictive ability than TNFAIP3 (AUROC = 0.611). Conclusion: TNFAIP3 and NLRP3 are significantly associated with the risk of MACEs in patients with CHF and NLRP3 demonstrates stronger predictive performance than TNFAIP3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.